PGJ2 antagonizes NF-κB-induced HIV-1 LTR activation in colonic epithelial cells

Virology

Volumn 380, Issue 1, 2008, Pages 1-11

  Boisvert, Mélissa ^a   Côté, Sandra ^a   Vargas, Amandine ^c   Pasvanis, Stamatoula ^a   Bounou, Salim ^b   Barbeau, Benoit ^c   Dumais, Nancy ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

HIV; Mucosal transmission; NF B; PGJ2; Transcription

Indexed keywords

BUTYRIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN J2; 9-DEOXY-DELTA-9-PROSTAGLANDIN D2; DRUG DERIVATIVE; PROSTAGLANDIN D2;

AIDS PATIENT; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CELL NUCLEUS; CELL STRAIN CACO 2; CELL STRAIN HT29; CHRONIC STRESS; COLON MUCOSA; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE ACTIVITY; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTESTINE EPITHELIUM CELL; LONG TERMINAL REPEAT; PRIORITY JOURNAL; REPORTER GENE; TRANSCRIPTION TERMINATION; VIRUS ACTIVATION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS TRANSCRIPTION; BIOSYNTHESIS; COLON; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM CELL; GENETICS; METABOLISM; PHYSIOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CACO-2 CELLS; COLON; EPITHELIAL CELLS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LUCIFERASES; NF-KAPPA B; PROSTAGLANDIN D2;

EID: 52049117618     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.07.023     Document Type: Article

References (96)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., and Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59 2 (1986) 284-291
2. Allred C.D., and Kilgore M.W. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol. Cell. Endocrinol. 235 1-2 (2005) 21-29
3. Amici C., Sistonen L., Santoro M.G., and Morimoto R.I. Antiproliferative prostaglandins activate heat shock transcription factor. Proc. Natl. Acad. Sci. U. S. A. 89 14 (1992) 6227-6231
4. Ankel H., Mittnacht S., and Jacobsen H. Antiviral activity of prostaglandin A on encephalomyocarditis virus-infected cells: a unique effect unrelated to interferon. J. Gen. Virol. 66 Pt 11 (1985) 2355-2364
5. Asin S.N., Fanger M.W., Wildt-Perinic D., Ware P.L., Wira C.R., and Howell A.L. Transmission of HIV-1 by primary human uterine epithelial cells and stromal fibroblasts. J. Infect. Dis. 190 2 (2004) 236-245
6. Belyakov I.M., and Berzofsky J.A. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20 3 (2004) 247-253
7. Bottero V., Busuttil V., Loubat A., Magne N., Fischel J.L., Milano G., and Peyron J.F. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res. 61 21 (2001) 7785-7791
8. Bottero V., Imbert V., Frelin C., Formento J.L., and Peyron J.F. Monitoring NF-kappa B transactivation potential via real-time PCR quantification of I kappa B-alpha gene expression. Mol. Diagn. 7 3-4 (2003) 187-194
9. Bouhlal H., Chomont N., Haeffner-Cavaillon N., Kazatchkine M.D., Belec L., and Hocini H. Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J. Immunol. 169 6 (2002) 3301-3306
10. Boyault S., Simonin M.A., Bianchi A., Compe E., Liagre B., Mainard D., Becuwe P., Dauca M., Netter P., Terlain B., and Bordji K. 15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett. 501 1 (2001) 24-30
11. Brockman J.A., Gupta R.A., and Dubois R.N. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115 5 (1998) 1049-1055
12. Chen F., and Harrison L.E. Ciglitazone induces early cellular proliferation and NF-kappaB transcriptional activity in colon cancer cells through p65 phosphorylation. Int. J. Biochem. Cell Biol. 37 3 (2005) 645-654
13. Chen B.K., Saksela K., Andino R., and Baltimore D. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J. Virol. 68 2 (1994) 654-660
14. Chenine A.L., Matouskova E., Sanchez G., Reischig J., Pavlikova L., LeContel C., Chermann J.C., and Hirsch I. Primary intestinal epithelial cells can be infected with laboratory-adapted strain HIV type 1 NDK but not with clinical primary isolates. AIDS Res. Hum. Retrovir. 14 14 (1998) 1235-1238
15. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., and Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J. Immunol. 164 3 (2000) 1364-1371
16. Collins K.B., Patterson B.K., Naus G.J., Landers D.V., and Gupta P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6 4 (2000) 475-479
17. Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev., Immunol. 2 10 (2002) 748-759
18. Delezay O., Koch N., Yahi N., Hammache D., Tourres C., Tamalet C., and Fantini J. Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29. Aids 11 11 (1997) 1311-1318
19. Dickerson M.C., Johnston J., Delea T.E., White A., and Andrews E. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. An application of the Bradford Hill criteria. Sex. Transm. Dis. 23 5 (1996) 429-440
20. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., Vidal H., and Auwerx J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272 30 (1997) 18779-18789
21. Fantini J., Baghdiguian S., Yahi N., and Chermann J.C. Selected human immunodeficiency virus replicates preferentially through the basolateral surface of differentiated human colon epithelial cells. Virology 185 2 (1991) 904-907
22. Fantini J., Yahi N., Baghdiguian S., and Chermann J.C. Human colon epithelial cells productively infected with human immunodeficiency virus show impaired differentiation and altered secretion. J. Virol. 66 1 (1992) 580-585
23. Fantini J., Cook D.G., Nathanson N., Spitalnik S.L., and Gonzalez-Scarano F. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. U. S. A. 90 7 (1993) 2700-2704
24. Faveeuw C., Fougeray S., Angeli V., Fontaine J., Chinetti G., Gosset P., Delerive P., Maliszewski C., Capron M., Staels B., Moser M., and Trottein F. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett. 486 3 (2000) 261-266
25. Fortin J.F., Cantin R., Lamontagne G., and Tremblay M. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J. Virol. 71 5 (1997) 3588-3596
26. Fukushima M., Kato T., Ota K., Arai Y., Narumiya S., and Hayaishi O. 9-deoxy-delta 9-prostaglandin D2, a prostaglandin D2 derivative with potent antineoplastic and weak smooth muscle-contracting activities. Biochem. Biophys. Res. Commun. 109 3 (1982) 626-633
27. Fukushima M., Kato T., Ueda R., Ota K., Narumiya S., and Hayaishi O. Prostaglandin D2, a potential antineoplastic agent. Biochem. Biophys. Res. Commun. 105 3 (1982) 956-964
28. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., Cornelissen I.L., Nottet H.S., KewalRamani V.N., Littman D.R., Figdor C.G., and van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100 5 (2000) 587-597
29. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., and Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5 6 (1999) 698-701
30. Golub E.I., Li G.R., and Volsky D.J. Induction of dormant HIV-1 by sodium butyrate: involvement of the TATA box in the activation of the HIV-1 promoter. Aids 5 6 (1991) 663-668
31. Griffin D.E., Wesselingh S.L., and McArthur J.C. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann. Neurol. 35 5 (1994) 592-597
32. Harouse J.M., Tan R.C., Gettie A., Dailey P., Marx P.A., Luciw P.A., and Cheng-Mayer C. In vitro infection of primate PBMC with simian/human immunodeficiency virus, SHIV(SF33A): correlation to in vivo outcome. J. Med. Primatol. 27 2-3 (1998) 81-86
33. Harouse J.M., Tan R.C., Gettie A., Dailey P., Marx P.A., Luciw P.A., and Cheng-Mayer C. Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology 248 1 (1998) 95-107
34. Harris S.G., Padilla J., Koumas L., Ray D., and Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol. 23 3 (2002) 144-150
35. Hayes M.M., Lane B.R., King S.R., Markovitz D.M., and Coffey M.J. Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects. J. Biol. Chem. 277 19 (2002) 16913-16919
36. Henderson A.J., Zou X., and Calame K.L. C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. J. Virol. 69 9 (1995) 5337-5344
37. Hinz B., Brune K., and Pahl A. 15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism. Biochem. Biophys. Res. Commun. 302 2 (2003) 415-420
38. Hortelano S., Castrillo A., Alvarez A.M., and Bosca L. Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J. Immunol. 165 11 (2000) 6525-6531
39. Hu J., Gardner M.B., and Miller C.J. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74 13 (2000) 6087-6095
40. Hughes-Fulford M., McGrath M.S., Hanks D., Erickson S., and Pulliam L. Effects of dimethyl prostaglandin A1 on herpes simplex virus and human immunodeficiency virus replication. Antimicrob. Agents Chemother. 36 10 (1992) 2253-2258
41. Ianaro A., Ialenti A., Maffia P., Pisano B., and Di Rosa M. Role of cyclopentenone prostaglandins in rat carrageenin pleurisy. FEBS Lett. 508 1 (2001) 61-66
42. Imaizumi T., Kumagai M., Hatakeyama M., Tamo W., Yamashita K., Tanji K., Yoshida H., and Satoh K. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits the expression of granulocyte-macrophage colony-stimulating factor in endothelial cells stimulated with lipopolysaccharide. Prostaglandins Other Lipid Mediat. 71 3-4 (2003) 293-299
43. Ito S., Narumiya S., and Hayaishi O. Prostaglandin D2: a biochemical perspective. Prostaglandins, Leukot. Essent. Fat. Acids 37 4 (1989) 219-234
44. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 6662 (1998) 82-86
45. Jozkowicz A., Dulak J., Prager M., Nanobashvili J., Nigisch A., Winter B., Weigel G., and Huk I. Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-gamma-independent manner. Prostaglandins Other Lipid Mediat. 66 3 (2001) 165-177
46. Kapoor M., Clarkson A.N., Sutherland B.A., and Appleton I. The role of antioxidants in models of inflammation: emphasis on l-arginine and arachidonic acid metabolism. Inflammopharmacology 12 5-6 (2005) 505-519
47. Kapoor M., Shaw O., and Appleton I. Possible anti-inflammatory role of COX-2-derived prostaglandins: implications for inflammation research. Curr. Opin. Investig. Drugs 6 5 (2005) 461-466
48. Kato M., Kusumi T., Tsuchida S., Tanaka M., Sasaki M., and Kudo H. Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. J. Cancer Res. Clin. Oncol. 130 2 (2004) 73-79
49. Kozak S.L., Platt E.J., Madani N., Ferro Jr. F.E., Peden K., and Kabat D. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J. Virol. 71 2 (1997) 873-882
50. Kozlowski P.A., and Neutra M.R. The role of mucosal immunity in prevention of HIV transmission. Curr. Mol. Med. 3 3 (2003) 217-228
51. Ladias J.A. Convergence of multiple nuclear receptor signaling pathways onto the long terminal repeat of human immunodeficiency virus-1. J. Biol. Chem. 269 8 (1994) 5944-5951
52. Lefebvre A.M., Chen I., Desreumaux P., Najib J., Fruchart J.C., Geboes K., Briggs M., Heyman R., and Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4 9 (1998) 1053-1057
53. Lefebvre M., Paulweber B., Fajas L., Woods J., McCrary C., Colombel J.F., Najib J., Fruchart J.C., Datz C., Vidal H., Desreumaux P., and Auwerx J. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J. Endocrinol. 162 3 (1999) 331-340
54. Li M., Pascual G., and Glass C.K. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20 13 (2000) 4699-4707
55. Mastromarino P., Conti C., Petruzziello R., De Marco A., Pica F., and Santoro M.G. Inhibition of Sindbis virus replication by cyclopentenone prostaglandins: a cell-mediated event associated with heat-shock protein synthesis. Antivir. Res. 20 3 (1993) 209-222
56. Meng G., Wei X., Wu X., Sellers M.T., Decker J.M., Moldoveanu Z., Orenstein J.M., Graham M.F., Kappes J.C., Mestecky J., Shaw G.M., and Smith P.D. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat. Med. 8 2 (2002) 150-156
57. Miller C.J., Alexander N.J., Sutjipto S., Joye S.M., Hendrickx A.G., Jennings M., and Marx P.A. Effect of virus dose and nonoxynol-9 on the genital transmission of SIV in rhesus macaques. J. Med. Primatol. 19 3-4 (1990) 401-409
58. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 1-2 (1983) 55-63
59. Neutra M.R., Frey A., and Kraehenbuhl J.P. Epithelial M cells: gateways for mucosal infection and immunization. Cell 86 3 (1996) 345-348
60. Padilla J., Kaur K., Cao H.J., Smith T.J., and Phipps R.P. Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J. Immunol. 165 12 (2000) 6941-6948
61. Pohlmann S., Baribaud F., and Doms R.W. DC-SIGN and DC-SIGNR: helping hands for HIV. Trends Immunol. 22 12 (2001) 643-646
62. Quivy V., Adam E., Collette Y., Demonte D., Chariot A., Vanhulle C., Berkhout B., Castellano R., de Launoit Y., Burny A., Piette J., Bours V., and Van Lint C. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J. Virol. 76 21 (2002) 11091-11103
63. Rabson A.B., and Lin H.C. NF-kappa B and HIV: linking viral and immune activation. Adv. Pharmacol. 48 (2000) 161-207
64. Ramis I., Rosello-Catafau J., Gomez G., Zabay J.M., Fernandez Cruz E., and Gelpi E. Cyclooxygenase and lipoxygenase arachidonic acid metabolism by monocytes from human immune deficiency virus-infected drug users. J. Chromatogr. 557 1-2 (1991) 507-513
65. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 6662 (1998) 79-82
66. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403 6765 (2000) 103-108
67. Royce R.A., Sena A., Cates Jr. W., and Cohen M.S. Sexual transmission of HIV. N. Engl. J. Med. 336 15 (1997) 1072-1078
68. Rozera C., Carattoli A., De Marco A., Amici C., Giorgi C., and Santoro M.G. Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely infected human cells. Evidence for a transcriptional block. J. Clin. Invest. 97 8 (1996) 1795-1803
69. Saez E., Tontonoz P., Nelson M.C., Alvarez J.G., Ming U.T., Baird S.M., Thomazy V.A., and Evans R.M. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med. 4 9 (1998) 1058-1061
70. Saez E., Rosenfeld J., Livolsi A., Olson P., Lombardo E., Nelson M., Banayo E., Cardiff R.D., Izpisua-Belmonte J.C., and Evans R.M. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev. 18 5 (2004) 528-540
71. Santoro M.G., Benedetto A., Carruba G., Garaci E., and Jaffe B.M. Prostaglandin A compounds as antiviral agents. Science 209 4460 (1980) 1032-1034
72. Santoro M.G., Jaffe B.M., Garaci E., and Esteban M. Antiviral effect of prostaglandins of the A series: inhibition of vaccinia virus replication in cultured cells. J. Gen. Virol. 63 2 (1982) 435-440
73. Santoro M.G., Benedetto A., Zaniratti S., Garaci E., and Jaffe B.M. The relationship between prostaglandins and virus replication: endogenous prostaglandin synthesis during infection and the effect of exogenous PGA on virus production in different cell lines and in persistently infected cells. Prostaglandins 25 3 (1983) 353-364
74. Santoro M.G., Favalli C., Mastino A., Jaffe B.M., Esteban M., and Garaci E. Antiviral activity of a synthetic analog of prostaglandin A in mice infected with influenza A virus. Arch. Virol. 99 1-2 (1988) 89-100
75. Santoro M.G., Rossi A., and Amici C. NF-kappaB and virus infection: who controls whom. Embo J. 22 11 (2003) 2552-2560
76. Sarraf P., Mueller E., Jones D., King F.J., DeAngelo D.J., Partridge J.B., Holden S.A., Chen L.B., Singer S., Fletcher C., and Spiegelman B.M. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 4 9 (1998) 1046-1052
77. Scher J.U., and Pillinger M.H. 15d-PGJ2: the anti-inflammatory prostaglandin?. Clin. Immunol. 114 2 (2005) 100-109
78. Schoonjans K., Staels B., and Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid. Res. 37 5 (1996) 907-925
79. Schreiber E., Matthias P., Muller M.M., and Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17 15 (1989) 6419
80. Shepard R.N., Schock J., Robertson K., Shugars D.C., Dyer J., Vernazza P., Hall C., Cohen M.S., and Fiscus S.A. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. J. Clin. Microbiol. 38 4 (2000) 1414-1418
81. Shimada T., Kojima K., Yoshiura K., Hiraishi H., and Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50 5 (2002) 658-664
82. Siebenlist U., Franzoso G., and Brown K. Structure, regulation and function of NF-kappa B. Annu. Rev. Cell Biol. 10 (1994) 405-455
83. Singh B., Halestrap A.P., and Paraskeva C. Butyrate can act as a stimulator of growth or inducer of apoptosis in human colonic epithelial cell lines depending on the presence of alternative energy sources. Carcinogenesis 18 6 (1997) 1265-1270
84. Skolnik P.R., Rabbi M.F., Mathys J.M., and Greenberg A.S. Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects. J. Acquir. Immune Defic. Syndr. 31 1 (2002) 1-10
85. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 4 (1998) 507-514
86. Spira A.I., Marx P.A., Patterson B.K., Mahoney J., Koup R.A., Wolinsky S.M., and Ho D.D. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183 1 (1996) 215-225
87. Stein T.P., Koerner B., Schluter M.D., Leskiw M.J., Gaprindachvilli T., Richards E.W., Cope F.O., and Condolucci D. Weight loss, the gut and the inflammatory response in aids patients. Cytokine 9 2 (1997) 143-147
88. Straus D.S., and Glass C.K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21 3 (2001) 185-210
89. Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., Sengchanthalangsy L.L., Ghosh G., and Glass C.K. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 97 9 (2000) 4844-4849
90. Sun S., Elwood J., and Greene W.C. Both amino- and carboxyl-terminal sequences within I kappa B alpha regulate its inducible degradation. Mol. Cell. Biol. 16 3 (1996) 1058-1065
91. Thomas S.C., Ryan M.A., Shanley T.P., and Wong H.R. Induction of the stress response with prostaglandin A1 increases I-kappaBalpha gene expression. Faseb J. 12 13 (1998) 1371-1378
92. Voboril R., and Weberova-Voborilova J. Constitutive NF-kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis. Neoplasma 53 6 (2006) 518-523
93. Wachtershauser A., Loitsch S.M., and Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem. Biophys. Res. Commun. 272 2 (2000) 380-385
94. Yamamoto N., Fukushima M., Tsurumi T., Maeno K., and Nishiyama Y. Mechanism of inhibition of herpes simplex virus replication by delta 7-prostaglandin A1 and delta 12-prostaglandin J2. Biochem. Biophys. Res. Commun. 146 3 (1987) 1425-1431
95. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., and Farrar W.L. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J. Biol. Chem. 275 7 (2000) 4541-4544
96. Zheng J., Xie Y., Campbell R., Song J., Wang R.Q., Chiu R., Berenson J., Razi M., Massachi S., Yang O.O., Chen I.S., and Pang S. gp120-independent HIV infection of cells derived from the female reproductive tract, brain, and colon. J. Acquir. Immune Defic. Syndr. 43 2 (2006) 127-136